Siyuan

What Siyuan does

Siyuan (Nanjing Siyuan Medical Technology Co., Ltd. / 南京思元医疗技术有限公司) is a privately held, Nanjing-based medical technology company founded in May 2019 that develops, manufactures, and sells innovative biomedical polymer materials for regenerative medicine and medical aesthetics. The company's technology is organized around two R&D platforms — a Medical Innovative Raw Materials platform (covering medical-grade polyester series such as PLLA, PCL, and PEG-PCL, regenerated silk fibroin series, and acellular extracellular matrix series) and a Bio-based Composite Materials platform (covering crosslinked dextran gel particles, recombinant human collagen, silk fibroin-collagen composites, and electrospun scaffolds). Proprietary methods include dual cross-linking technology for porous regenerated silk fibroin microspheres, antisolvent-induced recrystallization for high-porosity PLLA microspheres, and self/inter-crosslinking for recombinant humanized collagen.

Siyuan operates a 3,500 sqm GMP factory in Nanjing's Gaochun District with multiple production lines (vial filling, lyophilization, prefilled syringes, BFS single-dose, gels, dressings, ointments, sprays) and is building a second manufacturing subsidiary, Huzhou Yuan'en Biological, which broke ground in November 2024. The company's product business falls into three segments: (1) raw materials (regenerated silk fibroin in four grades, silk fibroin derivatives — microparticles, peptides, solution, gel — and biodegradable PLLA, PCL, and PEG-PCL microspheres) sold to medical device manufacturers; (2) Class II medical devices under the Meisiyi (每思怡) brand, including recombinant collagen paste, patch, spray, gynecological gel, liquid dressing, and gel dressing products; and (3) a forthcoming medical aesthetics pipeline anchored by silk fibroin-hyaluronate gel for temporal depression. The Meisiyi brand and bulk raw material sales reach end customers via a B2B direct sales model targeting hospitals, medical aesthetics institutions, cosmetic surgery clinics, and other manufacturers, with no publicly disclosed pricing.

As of the input period, Siyuan has secured a medical device production license (June 2023), ISO 13485/9001 certification for its Yangu Biotechnology subsidiary (October 2023), four NMPA master document registrations for silk fibroin raw materials, and 10+ Class II and III medical device registration certificates including the first domestic medical silk fibroin spray dressing registration (January 2025) and a silk fibroin gel dressing (July 2025), with three Class III products having completed clinical trials. Revenue and funding amounts are not publicly disclosed; the company has completed angel, Pre-A, and Series A rounds between 2021 and 2022 and operates as an independent private company chaired by Feng Zhugang (丰祝刚).

Name

Siyuan

Legal name

南京思元医疗技术有限公司

Website

https://siyuanyl.com

Company type

Private

Founded year

2019

Operating status

Operating

Short description

Siyuan is a private Nanjing-based medical technology company developing and manufacturing innovative biomedical polymer materials—silk fibroin, recombinant collagen, and biodegradable PLLA/PCL/PEG-PCL microspheres—for regenerative medicine and medical aesthetics, serving hospitals, aesthetics clinics, and device manufacturers.

Ownership category

akta.pro rank

Product category

Biomedical Materials & Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Plastics Material and Resin Manufacturing (325211)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL), Molded Fiber & Bio-composite Materials (natural fiber-reinforced plastics) (IMANANAE), Sterilization Consumables & Packaging (Wraps, Pouches, Indicators, Trays/Containers) (HLAHANAC)

Keywords

• Biomedical polymer materials
• Regenerative medicine materials
• Medical device manufacturing
• Silk fibroin materials
• Recombinant collagen dressings

Headquarters

HQ city

Nanjing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Medical Device Products Sales: Sale of registered medical devices including collagen dressings, silk fibroin products, and aesthetic injection materials to hospitals and clinics
2. Biomaterial Raw Materials Sales: Sale of biomedical raw materials including regenerated silk fibroin, PLLA microspheres, PCL microspheres, and PEG-PCL copolymers to other manufacturers
3. Cosmetic Product Sales: Sale of consumer-facing medical aesthetic products under the 每思怡 brand through medical institutions

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Siyuan researches, develops, produces, and sells biomedical polymer materials for regenerative medicine and medical aesthetics. The portfolio spans two technology platforms — Medical Innovative Raw Materials (PLLA, PCL, PEG-PCL, regenerated silk fibroin) and Bio-based Composite Materials — supporting finished Class II medical devices sold under the Meisiyi (每思怡) brand (recombinant collagen dressings, gels, sprays) and raw biomaterials sold to other manufacturers. Key product groups include regenerated silk fibroin raw materials, recombinant collagen wound care dressings, and biodegradable polymer microspheres used in tissue filling, drug delivery, and aesthetic procedures.

Product overview

Siyuan is a medical technology company specializing in innovative biomaterials for regenerative medicine. The portfolio consists of two core technology platforms — 'Medical Innovative Raw Materials' and 'Bio-based Composite Materials' — which together support three strategic business segments: innovative medical materials, medical aesthetics products, and regenerative medicine products. The finished products include the 'Meisiyi (每思怡)' brand series of recombinant human collagen dressings (paste, patch, spray, gynecological gel, liquid dressing, and gel dressing) registered as Class II medical devices. The raw materials segment includes regenerated silk fibroin raw materials (with four grades and four master document registrations: M2024048-000, M2024208-000, M2024146-000, M2024204-000), silk fibroin derivatives (micro particles, silk peptides, solution, gel), and biodegradable polymer microspheres (PLLA-Ms, PCL-Ms, PEG-PCL copolymer with master document M2023189-000). The company operates a 3,500 sqm GMP facility housing production lines for vials, lyophilization, prefilled syringes, BFS units, gels, dressings, ointments, sprays, and synthetic raw materials. A wholly-owned subsidiary, Nanjing Yugu Biotechnology (南京元谷生物科技有限公司), specializes in R&D, production, and sales of high-molecular medical new material synthesis raw materials and microspheres.

Differentiator

Problem solved

Functional benefit

Brands

• 每思怡: Sub-brand for recombinant collagen medical device products including spray dressings, patches, and ointment dressings.
• 元谷生物

Products and services

• Meisiyi Medical Recombinant Collagen Paste Dressing (每思怡医用重组胶原蛋白膏状敷料) Recombinant collagen-based paste dressing composed of recombinant collagen, carbomer, dimethicone, and other ingredients, providing physical barrier protection for minor wounds, abrasions, and post-procedure skin care. Available in 5g to 500g tube specifications.
• Meisiyi Medical Recombinant Collagen Dressing Patch (每思怡医用重组胶原蛋白敷贴) Dressing patch composed of recombinant collagen, trehalose, carbomer solution and non-woven fabric, forming a protective layer on wound surfaces for non-chronic wound care including post-procedure applications. Supplied in aluminum foil packaging, single-use.
• Meisiyi Medical Recombinant Collagen Spray Dressing (每思怡医用重组胶原蛋白喷剂敷料) Recombinant collagen spray dressing composed of recombinant collagen, trehalose, carbomer and other ingredients, dispensed via vertical spray bottle in specifications ranging from 1ml to 500ml.
• Medical Recombinant Collagen Gynecological Gel (医用重组胶原蛋白妇科凝胶) Recombinant collagen gynecological gel forming a protective gel membrane on the vaginal wall to provide physical isolation from pathogenic microorganisms. Packaged in medical polyethylene tubes, single-use.
• Medical Recombinant Collagen Liquid Dressing (医用重组胶原蛋白液体敷料) Sterile recombinant collagen liquid dressing containing recombinant collagen, sodium hyaluronate, and phosphate buffer, sterile-filtered and packaged in glass bottles. Suitable for superficial wounds and post-procedure wound care, available in 1mL to 20mL specifications.
• Medical Recombinant Collagen Gel Dressing (医用重组胶原蛋白凝胶敷料) Recombinant collagen gel dressing composed of recombinant collagen, trehalose, carbomer and other ingredients, providing care for superficial wounds including post-procedure applications. Packaged in polyethylene tubes, available in 1g to 100g specifications.
• Regenerated Silk Fibroin Raw Material (再生丝素蛋白原料) Regenerated silk fibroin raw material derived from natural silkworm cocoons, with four grades including medical device grade, medical device grade soluble, implantable grade (sterile, endotoxin<0.05EU/mg), and implantable grade soluble. Master document registrations: M2024048-000, M2024208-000, M2024146-000, M2024204-000.
• Silk Fibroin Micro Particles (丝素蛋白微粒) Silk fibroin nanoparticles prepared via freeze-drying and silk fibroin structure transformation, with customizable particle size range of 10-400 micrometers. Applicable in purification, drug delivery, biosensing, and anti-aging beauty applications.
• Silk Peptide (丝素肽) Small and large molecular weight silk peptides prepared via specialized enzymatic hydrolysis. Small molecular peptides offer excellent transdermal absorption; large molecular peptides provide superior film-forming and UV-blocking properties. Molecular weight: 500-3000Da. Available in 10g/100g/1kg/10kg packaging, for cosmetics and pharmaceutical applications.
• Silk Fibroin Solution (丝素蛋白溶液) High-purity silk fibroin solution prepared via multiple purification processes, with excellent stability and minimal visible particulates. Usable for forming various medical materials including coatings, films, sponges, hydrogels, and electrospun fibers.
• Silk Fibroin Gel (丝素蛋白凝胶) Silk fibroin gel prepared via physical crosslinking (without chemical crosslinking agents), featuring high biocompatibility and stability. Applicable in drug sustained release, gene vectors, and tissue filling applications.
• PLLA Emulsified Microspheres (聚左旋乳酸微球 / PLLA-Ms) Poly-L-lactic acid microspheres with customizable molecular weight, viscosity and particle size parameters. In tissue engineering and medical aesthetics, product forms include PLLA+CMC/HA lyophilized fibers, gels and suspensions. Also available as large-particle (PLLA-Mpl) and small-particle (PLLA-Mps) variants.
• Polycaprolactone Microspheres (聚己内酯微球 / PCL-Ms) Polycaprolactone microspheres synthesized via ring-opening polymerization of epsilon-caprolactone monomers under metal anionic complex catalyst. Offers excellent biocompatibility, biodegradability (fully degradable in 6-12 months), and compatibility with common plastics. Used as cell growth support material.
• PEG-PCL Copolymer (聚乙二醇-聚己内酯共聚物) Amphiphilic ABA triblock copolymer with low endotoxin, prepared via molecular structure design optimization and 'solvent-antisolvent+membrane filtration' purification. Forms nanomicelle colloidal solution when reconstituted with saline, enabling injection via 30-32G ultra-fine needles for mesotherapy. Master document registration: M2023189-000. Molecular weight: 8000-12000 (customizable).
• Medical Silk Fibroin Gel Dressing (医用丝素蛋白凝胶敷料) Medical silk fibroin gel dressing registered with NMPA (registration number 苏械注准20252141424). New material product launched in July 2025 that further enriches the company's silk fibroin-based product line.
• Medical Polysaccharide Liquid Dressing (医用多糖液体敷料) Medical polysaccharide liquid dressing; the first Class II medical device registration obtained by Siyuan, marking the start of the company's Class II product line.

Quantifiable outcome

• First medical silk fibroin spray dressing registration certificate in China
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• 江苏省蚕种所coreStrategic or Co-development Partner · 1 January 2021Joint establishment of medical silkworm breeding base covering the entire process from silkworm variety screening and quarantine to mulberry silkworm breeding, disease prevention, and silk extraction.
• 江苏桑蚕养殖示范园coreStrategic or Co-development Partner · 1 January 2021Coestablished standardized silkworm breeding system with Jiangsu Silkworm Breeding Demonstration Park for medical-grade silk fibroin production.
• 北京化工大学coreStrategic or Co-development Partner · 1 January 2020Established '生物医药高分子材料及器械联合研发中心' (Biomedical Polymer Materials and Devices Joint R&D Center) for joint development of medical polymer materials. Collaborated on PLLA porous microsphere technology development and industrialization at Yuan Gu Biology subsidiary.
• 中国药科大学minorStrategic or Co-development Partner · 1 January 2019R&D cooperation with China Pharmaceutical University for biomedical materials research.
• 南京大学minorStrategic or Co-development Partner · 1 January 2019R&D cooperation with Nanjing University for biomedical materials research.
• 东南大学minorStrategic or Co-development Partner · 1 January 2019R&D cooperation with Southeast University for biomedical materials research.
• 江苏中科院植物研究所minorStrategic or Co-development Partner · 1 January 2019R&D cooperation with Jiangsu Institute of Botany, Chinese Academy of Sciences for biomedical materials research.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Galderma: Galderma is a global dermatology and medical aesthetics leader with Sculptra (PLLA injectable), Restylane, and other regenerative aesthetics brands. It is a broad incumbent peer because its Sculptra PLLA franchise directly competes with Siyuan's PLLA microsphere technology in the same injectable aesthetics category.
• Huadong Medicine: Huadong Medicine is a large Chinese pharmaceutical company whose aesthetics subsidiary (Sinclair Pharma) offers Ellansé (PLLA-based dermal filler) and other regenerative injectables. It is a broad incumbent peer because it brings global aesthetics brands into the same Chinese hospital channels Siyuan targets.

Direct peers

• Evolved by Nature: Evolved by Nature is a US-based silk fibroin technology platform developing regenerative medical materials for wound care, aesthetics, and consumer applications. It is a direct peer because its silk fibroin platform is the closest international analogue to Siyuan's core silk fibroin technology stack.
• Bloomage Biotechnology: Bloomage is China's largest hyaluronic acid and biomedical materials company, with deep reach into medical aesthetics, skincare, and wound care channels. It is a direct peer given its overlapping biomaterial platform (HA, collagen, regenerative materials) and dominance of the same Chinese hospital and aesthetics clinic channels Siyuan targets.
• JINBO BIO (Jinbo Bio-Pharmaceutical): JINBO BIO is a Chinese recombinant collagen company with approved products in medical aesthetics, gynecology, and wound care. It is a highly direct peer because its recombinant collagen, gynecological gel, and Class II/III wound dressing portfolio closely mirrors Siyuan's Meisiyi line.
• Sofregen Medical: Sofregen is a US medical aesthetics company developing silk fibroin-based injectable scaffolds for soft tissue augmentation and regeneration. It is a direct peer because silk fibroin injectable scaffolds for medical aesthetics are an almost identical product concept to Siyuan's silk fibroin-hyaluronate gel for temporal depression correction.
• IMEIK Technology Development: IMEIK is one of China's leading medical aesthetics injectable companies with a broad portfolio of Class III hyaluronic acid and botulinum toxin products. It is a direct peer given its commercial dominance in the same hospital and aesthetic-clinic channels Siyuan targets with its PLLA and silk fibroin injectable pipeline.
• Hangzhou Singclean Medical Products: Singclean is a Chinese biomaterials and medical aesthetics company specializing in hyaluronic acid-based injectables, anti-adhesion products, and regenerative wound care. It is a direct peer given its overlapping injectable and wound-care biomaterial portfolio and Chinese B2B medical device channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Siyuan